vimarsana.com

Latest Breaking News On - Simon glerup - Page 1 : vimarsana.com

Teitur Trophics Raises EUR 28M in Series A Financing

Teitur Trophics Raises EUR 28M in Series A Financing to Advance the Development and Treatment for Neurodegenerative Diseases

Draupnir Bio establishes Scientific Advisory Board of European experts in cholesterol

Draupnir Bio establishes Scientific Advisory Board of European experts in cholesterol
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

Muna Therapeutics Raises $73 Million to Advance Neurodegenerative Disease Focus

Published: Jul 09, 2021 By Brandon May Muna Therapeutics, a private Denmark- and Belgium-based biopharmaceutical company founded in 2020, officially closed a $73 million Series A financing round. The company launches with the new funding to advance its focus on first-in-class small molecule therapies for neurodegenerative diseases. The Series A financing was led by Novo Holdings in conjunction with Sofinnova Partners, DROIA Ventures and LSP Dementia Fund. Additional investors who joined the financing round included Polaris Partners, Polaris Innovation Fund, Sanofi Ventures, V-Bio Ventures and VIB. Muna’s primary focus neurodegenerative diseases lead to disability and death of millions of people worldwide. There are currently no curative therapies available for many neurodegenerative conditions, a problem Muna hopes to address.

Muna Therapeutics Launches with US$ 73M Series A to Advance Novel Small Molecule Therapeutics for Neurodegenerative Diseases

Muna Therapeutics Launches with US$ 73M Series A to Advance Novel Small Molecule Therapeutics for Neurodegenerative Diseases - Financing co-led by Novo Holdings, Sofinnova Partners, Droia Ventures and LSP Dementia Fund, with participation from Polaris Partners, Polaris Innovation Fund, Sanofi Ventures, V-Bio Ventures and VIB - Developing small molecules to repair neuronal dysfunction and resolve neuroinflammation - Innovative drug discovery platform leveraging insights from novel targets and pathways, resilience to neurodegeneration and all-in-human validation News provided by Share this article Share this article COPENHAGEN, Denmark, July 9, 2021 /PRNewswire/  Muna Therapeutics ( Muna ), pioneering the development of first-in-class small molecule therapeutics for neurodegenerative diseases, today announced the successful closing of a US$ 73 million (EUR 60 million) Series A financing round. The investor syndicate was co-led by Novo Holdings, Sofinnova Partners, Droia Ventur

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.